Coronavirus protein (CoV protein)

Coronavirus proteins represent a diverse group of structural and non-structural proteins encoded by the Coronaviridae family, including SARS-CoV-2, SARS-CoV, and MERS-CoV (NIH, 2023, COVID-19 Treatment Guidelines). The structural proteins include the Spike (S) protein, which facilitates viral entry by binding to the host ACE2 receptor; the Envelope (E) and Membrane (M) proteins, involved in viral assembly; and the Nucleocapsid (N) protein, which packages the viral RNA (UniProt, 2021, P0DTC2). Non-structural proteins (nsps) are essential for viral replication, with the Main Protease (Mpro/3CLpro) and RNA-dependent RNA polymerase (RdRp) serving as primary therapeutic targets (Zhang et al., 2020, Science; Hillen et al., 2020, Nature). Drugs such as nirmatrelvir inhibit Mpro to prevent polyprotein processing, while remdesivir and molnupiravir target RdRp to disrupt viral RNA synthesis (PubChem, 2023, CID 155903259). Monoclonal antibodies like sotrovimab target the Spike protein to neutralize the virus and prevent infection (FDA, 2022). The rapid evolution of these proteins, particularly the Spike protein, poses significant challenges for long-term vaccine and therapeutic efficacy (CDC, 2023).

Other names

CoV proteinsSARS-CoV-2 proteinsViral structural proteinsNon-structural proteinsnsps

Therapeutic strategies involve the inhibition of viral entry via Spike protein neutralization (Hoffmann et al., 2020, Cell), the inhibition of viral polyprotein cleavage by targeting the Main Protease (Mpro) (Zhang et al., 2020, Science), and the termination of viral genome replication by inhibiting the RNA-dependent RNA polymerase (RdRp) (Hillen et al., 2020, Nature).